



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/086,177
Confirmation Number	1250
Filing Date	February 26, 2002
First Named Inventor	Tudan <i>et al.</i>
Group Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket No.	60568-8001.US02

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
/BEB/	1	5,350,836		Kopchick <i>et al.</i>	9/27/94	
	2	5,401,651		Walz	3/28/95	
	3	6,356,887	B1	Berenson, <i>et al.</i>	3/12/02	
	4	6,515,001	B2	Saxena, <i>et al.</i>	2/04/03	
	5	6,613,742		Huang <i>et al.</i>	9/2/03	
	6	6,693,134	B2	Saxena, <i>et al.</i>	2/17/04	
	7	6,875,738		Clarke Lewis <i>et al.</i>	4/05/05	
	8	6,946,445		Clarke Lewis <i>et al.</i>	9/20/05	
	9	2002/0165123	A1	Tudan, <i>et al.</i>	11/07/02	
	10	2002/0156034	A1	Tudan, <i>et al.</i>	10/24/02	
	11	2003/0125380	A1	Saxena, <i>et al.</i>	7/03/03	
	12	2003/0092674	A1	Saxena, <i>et al.</i>	5/15/03	
	13	2003/0045550	A1	Saxena, <i>et al.</i>	3/06/03	
	14	2003/0004136	A1	Saxena, <i>et al.</i>	1/02/03	
	15	2005/0059584	A1	Merzouk, <i>et al.</i>	3/17/05	
	16	2005/0164935	A1	Clarke Lewis <i>et al.</i>	7/28/05	
	17	2005/0265969	A1	Clarke Lewis <i>et al.</i>	12/1/05	
/BEB/	18	2006/0014682	A1	Clarke Lewis <i>et al.</i>	1/19/06	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
/BEB/	19	PCT	WO 91/04274		Genetics Institute, Inc. <i>et al.</i>	4/04/91		
/BEB/	20	PCT	WO 93/13206		British Bio Technology Limited	7/08/93		
/BEB/	21	PCT	WO 00/66112		PCT	9/11/00		
/BEB/	22	PCT	WO 01/76615		Salari, <i>et al.</i>	10/18/01		

EXAMINER

/Bridget E. Bunner/

DATE CONSIDERED

06/13/2007

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN		
				Application Number	10/086,177	
				Confirmation Number	1250	
				Filing Date	February 26, 2002	
				First Named Inventor	Tudan <i>et al.</i>	
				Group Art Unit	1647	
Examiner Name	Bunner, Bridget E.					
Attorney Docket No.	60568-8001_US02					
Sheet	2	of	6			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	23	PCT	WO 01/85196		Tudan, <i>et al.</i>	11/15/01		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	24	Bamerji, <i>et al.</i>, <i>Cell</i>, 33:729-740 (1983).		
	25	Belperio, <i>et al.</i>, <i>J. Leukoc. Biol.</i>, 68:1-8 (2000).		
	26	Denoist, <i>et al.</i>, <i>Nature</i>, 290:304-310 (1981).		
	27	Bollon, <i>et al.</i>, <i>J. of Clinical Hematology and Oncology</i>, 10:39-48 (1988).		
	28	Botstein, <i>et al.</i> "Making Mutations in Vitro and Putting them Back Into Yeast". Dept of Biol. Massachussetts Institute of Technology, 265-274 (1982).		
	29	Breach, J.R., <i>THE MOLECULAR BIOLOGY OF THE YEAST SACCHAROMYCES</i>, 445-470 (1981).		
	30	Breach, J.R., <i>Cell</i> 28:203-204 (1982).		
/BEB/	31	Buser, <i>et al.</i> , <i>Methods in Molecular Biology</i> , 138:143-148 (2000).		
	32	Calame, <i>et al.</i>, <i>Advances in Immunology</i>, 43:236-275 (1988).		
	33	Camper, <i>et al.</i>, <i>Genes & Development</i>, 3:537-546 (1988).		
	34	Genatiempo, Y., <i>Biochimie</i>, 68:505-515 (1986).		
	35	Colosimo, <i>et al.</i>, <i>BioTechniques</i>, 29:314-331 (2000).		
	36	Daugherty, <i>et al.</i>, <i>Chemokine Protocols</i>, 138:129-148 (2000).		
	37	Daugherty, <i>et al.</i>, <i>Methods in Molecular Biology</i>, 138:129-134 (2000).		

EXAMINER	DATE CONSIDERED
/Bridget E. Bunner/	06/13/2007
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/086,177
				Confirmation Number	1250
				Filing Date	February 26, 2002
				First Named Inventor	Tudan <i>et al.</i>
				Group Art Unit	1647
Examiner Name	Bunner, Bridget E.				
Sheet	3	of	6	Attorney Docket No.	60568-8001.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	38	DeNardo, et al., <i>Cancer</i>, <u>94</u>:1275-1286 (2002).		
	39	Dufour, J.H., et al., <i>The Journal of Immunology</i>, <u>167</u>(7077-7083):3195-3204 (2001).		
/BEB/	40	Eck et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 th Edition, Chapter 5, McGraw-Hill, NY (1996).		
	41	Edlund, et al., <i>Science</i>, <u>28</u>:912-916 (1985).		
/BEB/	42	Emanueli et al., <i>Br. J. Pharmacol.</i> , <u>133</u> (7):951-958 (2001).		
	43	"Expression in <i>E. coli</i>", <i>Methods in Enzymology</i>, <u>185</u>:119-129 (1990).		
	44	Francis, et al., <i>International Journal of Hematology</i>, <u>68</u>:1-18 (1998).		
	45	Gazitt, J. <i>Hematother. Stem Cell. Res.</i>, <u>10</u>:229-238 (2001).		
	46	Glick, et al., <i>J. of Industrial Microbiology</i>, <u>1</u>:277-282 (1987).		
	47	Glimm, et al., <i>Blood</i>, <u>99</u>(9):3434-3437 (2002).		
	48	Gold, et al., <i>Ann Rev. Microbiol.</i>, <u>35</u>:383-403 (1981).		
/BEB/	49	Gonzalo et al., <i>J. Immunology</i> , <u>165</u> (1):499-508 (2000).		
	50	Gottesman, S., <i>Ann. Rev. Genet.</i>, <u>18</u>:415-441 (1984).		
	51	Hamer, et al., <i>J. of Molecular and Applied Genetics</i>, <u>1</u>:273-288 (1982).		
	52	Hattori, et al., <i>Blood</i>, <u>97</u>:3354-3359 (2001).		
	53	Hebert, et al., <i>The J. of Biological Chemistry</i>, <u>266</u>(26):18989-18994 (1991).		
/BEB/	54	Hessing et al., <i>Blood</i> , <u>94</u> (10 Suppl.): pg.100A (1999).		

EXAMINER	DATE CONSIDERED
/Bridget E. Bunner/	06/13/2007
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/086,177
				Confirmation Number	1250
				Filing Date	February 26, 2002
				First Named Inventor	Tudan <i>et al.</i>
				Group Art Unit	1647
Examiner Name	Bunner, Bridget E.				
Sheet	4	of	6	Attorney Docket No.	60568-8001.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	55	Hunter et al., <i>Blood</i>, <u>86</u>(12):4400-4400 (1995).		
	56	John Jr., et al., <i>Reviews of Infectious Diseases</i>, <u>8</u>(5):693-704.		
	57	Johnston, et al., <i>Proc. Natl. Acad. Sci. USA</i> <u>79</u>:6971-6975 (1982).		
	58	Kaltsas, et al., <i>Ann. Oncol.</i>, <u>12</u>(Supp. 2):S47-50 (2001).		
	59	Kessel, et al., <i>Science</i>, <u>249</u>:374-379 (1990).		
	60	Kieseler, et al., <i>Brain</i>, <u>125</u>:823-824 (2002).		
	61	Lane, et al., <i>Blood</i>, <u>96</u>:4152-4159 (2000).		
	62	Lejeune, et al., <i>Cancer Immunol. Immunother.</i>, <u>38</u>:167-170 (1984).		
/BEB/	63	Li, et al., <i>J. Biol. Chem.</i> , <u>273</u> (26):16442-16445 (1998).		
	64	Mach, et al., <i>Gurr. Opin. Immunol.</i>, <u>12</u>:571-575 (2000).		
/BEB/	65	Maniatis, <i>Cell Biology</i> , <u>3</u> :564-608 (1980).		
/BEB/	66	Marshall et al., <i>Science</i> , <u>269</u> (5227):1050, 1052-1055 (1995).		
	67	McKnight, S.L., <i>Cell</i>, <u>31</u>:355-365 (1982).		
	68	McLaughlin, S., et al., <i>J. Virology</i>, <u>62</u>(6):1963-1973 (1988).		
	69	Miller, et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes," 277-297 (1986).		
	70	Miller, et al., <i>J. Immunol.</i> <u>143</u>(6):2007-2016, (1989).		
	71	MOLECULAR CLONING A LABORATORY MANUAL, Third Ed., Vol. 1, (2001).		

EXAMINER	DATE CONSIDERED
/Bridget E. Bunner/	06/13/2007
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/086,177
				Confirmation Number	1250
				Filing Date	February 26, 2002
				First Named Inventor	Tudan <i>et al.</i>
				Group Art Unit	1647
				Examiner Name	Bunner, Bridget E.
Sheet	5	of	6	Attorney Docket No.	60568-8001.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	72	Moss, J., <i>American Chem. Soc.</i> <u>16</u>:423-446, (1995).		
	73	Nagasawa, <i>Int. J. Hematol.</i> <u>72</u>:400-411, (2000).		
/BEB/	74	Nanki et al., <i>J. Immunology</i> , <u>165</u> (11):6590-6598 (2000).		
	75	Nomura, et al., <i>Int. J. Cancer</i>, <u>91</u>:607-606 (2001).		
/BEB/	76	Orkin et al., Report and Recommendations of the Panel to assess the NIH Investment in Research on Gene Therapy, available through NIH or at http://www.nih.gov/news/panelrep (1995).		
/BEB/	77	Perez, et al., <i>Exp. Hematol.</i> , <u>32</u> :300-307 (2004).		
	78	Pinkert, et al., <i>Genes & Development</i>, <u>1</u>:268-276 (1987).		
	79	Ponath, et al., <i>Methods in Molecular Biology</i>, <u>138</u>:113-120 (2000).		
	80	Queen, et al., <i>Cell</i>, <u>33</u>:741-748 (1983).		
/BEB/	81	Rissanen et al., Gene Therapy for Therapeutic Angiogenesis in Critically Ischaemic Lower Limb-on the way to the clinic, <i>Eur. J. Clin Invest.</i> , <u>31</u> (8):651-666 (2001).		
/BEB/	82	Ross, Gene Therapy in the United States: A Five-Year Status Report, <i>Hum. Gene Ther.</i> , <u>7</u> (14):1781-1790 (1996).		
/BEB/	83	Rubanyi, The Future of Human Gene Therapy, <i>Mol. Aspects Med.</i> , <u>22</u> (3):113-142 (2001).		
	84	Rubin, G.M., <i>Science</i>, <u>240</u>:1453-1459 (1988).		
/BEB/	85	Schwaab et al., <i>Semin Thromb. Hemostat.</i> , <u>27</u> (4):417-424 (2001).		
	86	Schwarz, et al., <i>Nat. Rev. Drug Discov.</i>, <u>1</u>:347-358 (2002).		
	87	Silver, et al., <i>Proc. Natl. Acad. Sci. USA</i>, <u>81</u>:5951-5955 (1984).		

EXAMINER	DATE CONSIDERED
/Bridget E. Bunner/	06/13/2007
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/086,177
				Confirmation Number	1250
				Filing Date	February 26, 2002
				First Named Inventor	Tudan <i>et al.</i>
				Group Art Unit	1647
Examiner Name	Bunner, Bridget E.				
Sheet	6	of	6	Attorney Docket No.	60568-8001.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	88	Smith, et al., Gene, 07:31-40 (1968).		
/BEB/	89	Tudan, et al., J. Med. Chem., 45(10):2024-2031 (2002).		
	90	Wada, et al., Nucleic Acids Research, 20:2111-2116 (1992).		
	91	Wang, W., et al., The Journal of Biological Chemistry, 275(29):22313-22323 (2000).		
	92	Winoto, et al., The EMBO J., 8(9):729-733 (1989).		
/BEB/	93	Zhong, et al., Exp. Hematol., 32:470-475 (2004).		

EXAMINER	/Bridget E. Bunner/	DATE CONSIDERED	06/13/2007
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).			